Pharmacokinetics and Tissue Distribution of Recombinant Human Transforming Growth Factor Beta1 After Topical and Intravenous Administration in Male Rats |
| |
Authors: | Zioncheck Thomas F Chen Sharon A Richardson Louise Mora-Worms Marina Lucas Catherine Lewis Derf Green James D Mordenti Joyce |
| |
Institution: | (1) Department of Safety Evaluation, Genentech, Inc., South San Francisco, California, 94080-4990;(2) Department of Medicinal and Analytical Chemistry, Genentech, Inc., South San Francisco, California, 94080-4990 |
| |
Abstract: | Recombinant human transforming growth factor beta (rhTGF-1) enhances the healing process after topical application to various animal wound models. A detailed pharmacokinetic and tissue distribution study was performed to support the clinical development of rhTGF-1 for wound healing indications. Rats received radioiodinated or unlabeled rhTGF-1 as an intravenous (iv) bolus or as a topical formulation applied to a full thickness wound. Plasma concentrations of TGF-1 were estimated from TCA-precipitable radioactivity or were measured by ELISA. Following iv administration, the initial half-life was rapid (<11 min), regardless of whether radi-olabeled or unlabeled rhTGF-1 was used. The terminal half-life was long (163 min) when the test material was radioiodinated and administered as a trace dose and relatively short (61 min) when given at high doses and assayed by ELISA. Analysis of plasma radioactivity by SDS-PAGE revealed a time-dependent clearance of the 25-kDa parent molecule without a significant appearance of lower molecular weight radiolabeled metabolites. The majority of the radioactivity was associated with highly perfused organs, known iodide elimination pathways, and the thyroid at 1 and 8 hr after iv injection. After topical administration of a high dose (0.8 mg/kg), no immunoreactive TGF-1 was detectable in plasma samples taken over a 48-hr period. However, trace amounts (0.05 ng/mL) of acid-precipitable radioactivity were detected in plasma after topical application of 125I]rhTGF-1 (1 µg/kg, 126 µCi/kg). A significant portion (35%) of the 125I]rhTGF-1 persisted intact (25 kDa) at the wound site 24 hr after application. In conclusion, rhTGF-1 was rapidly cleared after iv bolus administration and distributed primarily to the liver, lungs, kidney, and spleen. Little systemic exposure was observed after applying a single topical dose of rhTGF-1 to a wound, and the intact molecule persisted at the wound site. |
| |
Keywords: | recombinant human transforming growth factor beta1 wound-healing pharmacokinetics plasma-based enzyme-linked immunosorbent assay (ELISA) tissue distribution |
本文献已被 SpringerLink 等数据库收录! |
|